El EM/SFC es una enfermedad física de larga duración cuyo rasgo distintivo es el malestar posesfuerzo, un desplome retardado que desencadena el esfuerzo. La terapia de ejercicio graduado, en su día estándar, se retiró en 2021.
El pilar ahora es el manejo del ritmo de actividad (pacing): aprender a vivir dentro de la energía de la que dispones para desplomarte con menos frecuencia. El cuidado diario es un manejo constante de los síntomas del sueño no reparador, del mareo y la taquicardia de los problemas ortostáticos, y del dolor.
Practice Ranking
Every practice we track for Chronic Fatigue Syndrome (ME/CFS): What the Evidence Supports, ranked by how well the evidence supports it for this condition. Strength describes the evidence, not our endorsement.
3 practices · 1 to start with
| # | Practice | Evidence | Type | Cost | Effort | Results In | Add to plan |
|---|---|---|---|---|---|---|---|
| 1 | Pacing: How Staying Within Your Energy Envelope Prevents Crashes in ME/CFS and Long COVID The frontline approach: stay within your energy envelope to avoid post-exertional crashes. Management, not a cure. | Moderate | Self-Directed | – | – | – | |
| 2 | Cognitive Behavioral Therapy: What It Treats, How Strong the Evidence Is, and How to Start Supportive CBT can help some people cope, alongside pacing; it is not a cure and remains contested in the patient community. | Emerging | Self-Directed | Free to $$ | Moderate to Hard | Weeks | |
| 3 | Coenzyme Q10: What the Trials Show for Heart Failure, Migraine, and Statin Muscle Pain Coenzyme Q10 plus NADH lowered exercise heart rate and eased fatigue over 8 weeks in one 80-person trial. | Preliminary | Supplement | $ to $$ | Easy | Weeks to Months | |
Default order puts the best-supported practices first, with self-directed care ahead of clinical options. Click any row to open the practice.
ME/CFS turns on one feature: post-exertional malaise. Ordinary tiredness has dozens of causes and is covered on the Fatigue page. When the illness begins after a COVID infection, it overlaps with Long COVID.
What It Is
Myalgic encephalomyelitis, also called chronic fatigue syndrome, is a long-term physical illness marked by disabling fatigue that rest does not fix.
One feature sets it apart from ordinary tiredness: post-exertional malaise.
A small physical or mental effort triggers a delayed, disproportionate crash, often a day or two afterward, that can last for days or weeks.
There is no single blood test; a doctor recognizes ME/CFS by its pattern:
- months of fatigue that does not lift with rest,
- the crash after exertion,
- unrefreshing sleep,
- trouble with memory, concentration, or standing upright.
Those same symptoms also point to four treatable conditions: thyroid disease, sleep apnea, anemia, celiac disease. The diagnosis is settled only after each is ruled out, so an early, careful assessment matters.
Severity spans a wide range, and doctors group it in three bands:
- Mild: activity is cut by around half; many keep working or studying by giving up leisure, social life and rest margins, then crash after any overexertion.
- Moderate: most people are housebound, managing daily tasks only in short bursts with rest between.
- Severe and very severe: people are largely or entirely bed-bound, often unable to tolerate light, sound or being moved, and may need help with eating and washing. Trivial-looking exertions can cause a lasting setback. This most severely affected group is often under-recognized.
Many also feel worse upright: light-headed and unsteady, with palpitations that ease on lying down. This overlaps with postural tachycardia syndrome (POTS), one more form of orthostatic intolerance and treatable on its own. ME/CFS affects women more often than men.
How It Works
The crash has a measurable physical basis. On a maximal exercise test repeated on two consecutive days, people with ME/CFS look much like healthy but inactive people on day one. On day two they cannot repeat it, reaching lower oxygen consumption and workload at both peak effort and the anaerobic threshold. Healthy sedentary controls reproduce their day-one results. That day-one-to-day-two drop is a physical marker of post-exertional malaise, and only the two-day test reveals it. It points away from simple deconditioning: the control group was inactive too, yet recovered normally. A classification model detected the two-day drop with 95.1% accuracy.
ME/CFS often begins after an infection, so in many people it is a post-viral illness. COVID made the overlap plain. Among people still severely fatigued six months after a mild or moderate infection, 19 of 42 met the full 2003 Canadian consensus criteria for ME/CFS, post-exertional malaise included. They closely resembled patients whose illness had followed other infections. What triggers it in one person, and the immune and metabolic mechanisms behind the crash, are still being worked out.
What Helps
Pacing comes first. Also called energy management, it means learning where your limit sits and staying under it, so effort does not tip into a crash. Pacing keeps you as active as the illness allows without slipping into all-day bed rest. It does not cure ME/CFS; it lowers how often you crash and makes a fluctuating illness more livable. In patient surveys it is the approach people rate most helpful and least likely to set them back. That is why current guidance builds care around it. A large trial has not yet tested individualized pacing head to head, so for now it rests on patient experience and today's guidance. The PACE trial tested a separate, fixed pacing protocol, which did no better than usual specialist care; it is not the same as day-to-day energy management. The practical core is learning your own early warning signs and stopping before you reach the limit.
The exercise question needs the most care, because getting it wrong has harmed people. For years, graded exercise therapy, a program of steadily increasing activity, was the standard, built on the PACE trial. A Cochrane review still finds a small fatigue benefit on low-to-moderate-certainty evidence. Large patient surveys reported high rates of harm from graded exercise. When PACE was reanalyzed using the study's own original scoring rules, the recovery claims came out far smaller than first reported, and no better than the comparison group. Most trials showing a benefit used broad entry rules that did not require post-exertional malaise. So they may not apply to the people whose effort reliably triggers a crash. Weighing the harm reports against the deflated recovery claims, the 2021 UK national guideline withdrew graded exercise therapy, and it is no longer offered.
Talk therapy and brain-retraining are sometimes sold as treatments for the illness itself. In that same reanalysis, cognitive behavioral therapy did not change the illness, though it helps some people cope. Brain-retraining programs such as DNRS are marketed directly at ME/CFS. These programs are built around nervous-system sensitization, which is real, but no controlled trial has tested the program itself. Any claim that it reverses the illness is unconfirmed, the research to judge it has not been done.
No drug changes the course of ME/CFS. Rituximab, a B-cell-depleting drug, was the most-watched attempt and matched placebo in a well-run 151-patient trial: response rates ran 26.0% on the drug and 35.1% on placebo. That closed off a leading disease-modifying hope, though it speaks only to rituximab and leaves other immune approaches still under study. A small trial of coenzyme Q10 plus NADH is preliminary and industry-affiliated. In one 80-person study it eased fatigue and lowered the heart rate people reached on an exercise test over eight weeks. It did nothing for pain or sleep, and one author was affiliated with a nutrition company. Beyond these, chronic-fatigue supplement protocols and private tests are sold directly to consumers online. Most are unregulated and none has been tested in a controlled trial. That does not prove they do nothing, it means the evidence is not there yet.
Most care is steady, symptom-by-symptom work you largely run yourself, and four pieces matter most:
- Orthostatic intolerance and POTS, one of the more treatable pieces. Options include more fluids and salt where a doctor agrees, compression garments, standing up slowly, and medication a doctor may add.
- Unrefreshing sleep and pain, each treated as a problem in its own right.
- Aids, help at home and adjustments at work or school that suit a changing illness.
- Anything that adds to the load (thyroid disease, sleep apnea, low mood) found and treated.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
Energy And Fatigue
El rituximab no funcionó mejor que el placebo (respuesta del 26.0 % frente al 35.1 %) en un ensayo con 151 pacientes
Un ensayo bien realizado con rituximab, un fármaco que reduce las células B del sistema inmunitario, encontró que no funcionó mejor que el placebo para el SFC/EM, cerrando uno de los intentos más observados de encontrar un tratamiento que modifique la enfermedad.
En un ensayo multicéntrico aleatorizado, doble ciego y controlado con placebo, con 151 pacientes que cumplían los criterios canadienses, el rituximab produjo una tasa de respuesta global del 26.0 % frente al 35.1 % con placebo (diferencia de -9.2 puntos porcentuales, IC del 95 %: -23.3 a 5.5), y los grupos no difirieron en la puntuación de fatiga a lo largo de 24 meses ni en ninguna medida secundaria. Se produjeron eventos adversos graves en el 26 % del grupo de rituximab y en el 19 % del grupo de placebo. Measured in: 151 adults aged 18 to 65 with ME/CFS by Canadian consensus criteria, ill for 2 to 15 years, at five Norwegian hospitals. Se trató de un ensayo ciego con potencia estadística adecuada, por lo que el resultado nulo es sólido para el rituximab, pero se aplica a este fármaco en particular y no descarta otros enfoques inmunitarios en estudio; el resultado principal fue autoinformado.
Who this may not transfer to:Both sexes were enrolled with a female majority typical of ME/CFS; the trial did not report sex-stratified response rates.
The study · 1
Fluge et al., B-lymphocyte depletion in patients with myalgic encephalomyelitis/chronic fatigue syndrome: a randomized, double-blind, placebo-controlled trial · Ann Intern Med 2019;170(9):585-93
En 8 ensayos con 1518 adultos, la terapia de ejercicio probablemente alivió un poco la fatiga, con certeza de baja a moderada
Los ensayos combinados encontraron que el ejercicio gradual probablemente redujo un poco la fatiga en comparación con no hacer nada, pero la certeza era baja, si causaba daño no estaba claro, y la mayoría de los ensayos no reclutaron específicamente a personas con el patrón de colapso tras el esfuerzo.
Una revisión Cochrane de 8 ensayos aleatorizados en 1518 adultos encontró que la terapia de ejercicio, en su mayoría actividad aeróbica gradual, probablemente redujo la fatiga al final del tratamiento en comparación con el control pasivo, con evidencia de certeza de baja a moderada. La revisión juzgó incierto el efecto sobre los daños graves, y la mayoría de los ensayos incluidos reclutaron bajo criterios amplios que no requerían malestar posesfuerzo. Measured in: 1,518 adults with a primary diagnosis of chronic fatigue syndrome across 8 randomized controlled trials, using a range of diagnostic criteria. La mayoría de los ensayos usaron definiciones amplias que no requerían malestar posesfuerzo, por lo que los resultados pueden no describir a las personas para quienes el esfuerzo desencadena de forma fiable un colapso; la revisión señaló incertidumbre sobre los daños, y su propio editor ha declarado que se está actualizando.
Who this may not transfer to:Trials enrolled both sexes with a female majority typical of ME/CFS cohorts; the review did not report sex-stratified effects.
The study · 1
Larun et al., exercise therapy for chronic fatigue syndrome · Cochrane Database Syst Rev 2019;10:CD003200
Reanalizados según su propio protocolo original, la TCC y el ejercicio gradual del PACE no funcionaron mejor que el grupo de comparación
Cuando los datos del ensayo PACE se analizaron de la manera que su propio plan había especificado, las cifras de recuperación y mejora para la TCC y el ejercicio gradual fueron mucho más bajas de lo reportado inicialmente y no mejores que el grupo de comparación, con cualquier pequeña ganancia limitada a cómo se calificaban las personas a sí mismas.
Un reanálisis del ensayo PACE usando su propio protocolo originalmente especificado encontró que, tras corregir por las comparaciones planificadas, la TCC y el ejercicio gradual no superaron significativamente al grupo control en la mejora general, y las tasas de recuperación fueron consistentemente bajas y no difirieron entre grupos. Los efectos significativos estuvieron casi enteramente en las medidas autoinformadas y no duraron más de dos años. Measured in: Reanalysis of data from the 641-patient PACE randomized trial (Oxford criteria), using protocol-specified outcomes obtained through a Freedom of Information request. Este es un reanálisis de un ensayo existente, no un estudio nuevo, y hereda los límites de diseño del ensayo original, incluida una definición de caso amplia y resultados primarios autoinformados sin cegamiento; esas mismas características son la razón por la cual los autores advierten que las modestas ganancias autoinformadas podrían reflejar sesgo de reporte.
Who this may not transfer to:The underlying PACE trial enrolled both sexes with a female majority; the reanalysis did not report sex-stratified outcomes.
The study · 1
Wilshire et al., rethinking the treatment of chronic fatigue syndrome: a reanalysis and evaluation of findings from a recent major trial of graded exercise and CBT · BMC Psychol 2018;6(1):6
El programa estructurado de ritmo (pacing) en el estudio PACE no funcionó mejor que la atención especializada a las 52 semanas
El programa específico y estructurado de dosificación del esfuerzo probado en el ensayo principal no funcionó mejor que la atención especializada habitual, lo cual es una cuestión separada del manejo diario de energía que los pacientes y la guía actual describen como dosificación del esfuerzo.
En el ensayo aleatorizado PACE de 641 pacientes, el protocolo formal probado como terapia de dosificación adaptativa del esfuerzo, añadido a la atención médica especializada, no mejoró la fatiga ni la función física más que la atención médica especializada sola a las 52 semanas. Measured in: 641 adults meeting Oxford criteria for chronic fatigue syndrome, recruited from six UK secondary-care clinics. La terapia de ritmo adaptativo tal como se protocolizó en este ensayo no es lo mismo que el manejo individualizado de la energía que hoy se llama pacing, por lo que este resultado nulo se refiere a un protocolo formal concreto, no al enfoque general; el ensayo también utilizó la definición amplia de Oxford, que no exige malestar posesfuerzo.
Who this may not transfer to:Both sexes were enrolled with a female majority; the trial did not report sex-stratified primary outcomes.
The study · 1
White et al., comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial · Lancet 2011;377(9768):823-36
En un ensayo con 80 personas, la coenzima Q10 más NADH redujo la frecuencia cardíaca durante el ejercicio y alivió la fatiga en 8 semanas
En un ensayo pequeño, un suplemento de coenzima Q10 y NADH redujo la frecuencia cardíaca alcanzada durante una prueba de esfuerzo y alivió la sensación de fatiga a lo largo de ocho semanas, aunque no tuvo efecto sobre el dolor ni el sueño.
En un ensayo de prueba de concepto de 8 semanas, aleatorizado, doble ciego y controlado con placebo, con 80 pacientes, la coenzima Q10 más NADH redujo significativamente la frecuencia cardíaca máxima alcanzada durante una prueba de esfuerzo en bicicleta en la semana 8 (P=0.022) y redujo la fatiga percibida frente al placebo (P=0.03). El dolor y el sueño no mejoraron. La combinación fue bien tolerada. Measured in: 80 adults with chronic fatigue syndrome in a single-center trial in Barcelona. El ensayo fue pequeño, duró solo ocho semanas, y su criterio principal fue una medida de la frecuencia cardíaca durante el ejercicio, no el funcionamiento diario, por lo que el hallazgo es preliminar; uno de los autores estaba afiliado a una empresa de nutrición.
Who this may not transfer to:Both sexes were enrolled with a female majority; the trial did not report sex-stratified effects.
The study · 1
Castro-Marrero et al., effect of coenzyme Q10 plus nicotinamide adenine dinucleotide supplementation on maximum heart rate after exercise testing in chronic fatigue syndrome: a randomized, controlled, double-blind trial · Clin Nutr 2016;35(4):826-34
Measurement And Diagnosis
Aproximadamente el 0.89 % de las personas tienen SFC/EM, las mujeres de 1.5 a 2 veces más que los hombres
Se estima que aproximadamente 0.9 de cada 100 personas tienen SFC/EM según los criterios habituales, y las mujeres se ven afectadas aproximadamente de una vez y media a dos veces más que los hombres, aunque la cifra cambia mucho según cómo se cuente.
Un metaanálisis de 46 estudios que abarcaron a más de 1,085,000 personas estimó la prevalencia del SFC/EM en un 0.89 % según la definición de caso más comúnmente usada (CDC-1994), con una estimación de metaanálisis de efectos aleatorios en todas las definiciones del 0.68 % (IC del 95 %: 0.48 a 0.97). Las estimaciones variaron ampliamente según la definición de caso y cómo se determinaba el diagnóstico, desde el 0.09 % por diagnóstico médico hasta el 1.14 % por entrevista. Las mujeres se vieron afectadas aproximadamente de 1.5 a 2 veces más que los hombres. Measured in: More than 1,085,000 participants from community-based surveys and primary care sites across 46 studies published from 1980 to 2018. Las estimaciones variaron ampliamente según la definición de caso y el método diagnóstico usado, por lo que ninguna cifra única de prevalencia es definitiva; los autores señalan la falta de una prueba diagnóstica objetiva como la razón principal de la dispersión.
Who this may not transfer to:Both sexes were included; the review found women affected about 1.5 to 2 times as often as men across every subgroup analyzed.
The study · 1
Lim et al., systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) · J Transl Med 2020;18(1):100
19 de 42 personas con fatiga persistente post-COVID cumplieron todos los criterios del SFC/EM
En un estudio de personas que seguían exhaustas seis meses después de una infección leve o moderada por COVID, casi la mitad cumplía todos los criterios del SFC/EM, incluido el colapso tras el esfuerzo, lo que demuestra que la enfermedad puede ser desencadenada por la COVID de forma similar a como puede seguir a otras infecciones.
En una cohorte prospectiva de 42 personas con fatiga persistente de moderada a grave e intolerancia al esfuerzo seis meses después de una COVID-19 leve a moderada, 19 cumplieron los criterios de consenso canadienses de 2003 para el SFC/EM, incluido el malestar posesfuerzo. El grupo con SFC/EM posterior a la COVID se asemejó a una cohorte emparejada cuyo SFC/EM había seguido a otras infecciones. Measured in: 42 adults (29 women, 13 men, median age 36.5) with persistent post-COVID fatigue, compared with an age- and sex-matched post-infectious non-COVID ME/CFS cohort. What could explain it instead: People who volunteer for a post-COVID fatigue study are selected for severity, so the share meeting ME/CFS criteria here is likely higher than among all people who catch COVID; unmeasured prior health differences could also shape who develops lasting symptoms.. Se trata de una pequeña cohorte observacional de la primera ola pandémica, por lo que la proporción de quienes desarrollan SFC/EM tras la COVID no se puede generalizar a partir de ella; establece que la superposición es real, sin medir su frecuencia.
Who this may not transfer to:Both sexes were included (29 women, 13 men); the cohort was too small for reliable sex-stratified analysis.
The study · 1
Kedor et al., a prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity · Nat Commun 2022;13(1):5104
How it works
Una segunda prueba de ejercicio un día después expone una caída que distingue el SFC/EM de los controles con un 95.1 % de precisión
Las personas con SFC/EM rindieron igual que personas sanas pero inactivas en una prueba de ejercicio el primer día, pero un día después sus cuerpos no pudieron repetirla, una caída medible que da al colapso tras el esfuerzo un marcador físico que una sola prueba pasaría por alto.
En una prueba de ejercicio cardiopulmonar de dos días, 51 mujeres con SFC/EM y 10 mujeres control sedentarias rindieron de forma similar el día uno, pero el día dos el grupo con SFC/EM alcanzó un consumo de oxígeno y una carga de trabajo significativamente más bajos tanto en el esfuerzo máximo como en el umbral anaeróbico, mientras que los controles reprodujeron sus resultados. Un modelo de clasificación separó a los grupos con un 95.1 % de precisión en la segunda prueba. Un estudio independiente encontró de forma similar que los pacientes con SFC/EM no podían reproducir su consumo máximo de oxígeno el segundo día. Measured in: 51 women with ME/CFS and 10 sedentary control women, each completing two maximal exercise tests 24 hours apart. What could explain it instead: Deconditioning from inactivity could in principle lower exercise capacity, but the control group was also sedentary and reproduced their day-one results, which points away from deconditioning alone as the explanation for the day-two drop.. Solo se incluyó a pacientes lo bastante bien como para completar dos pruebas de ejercicio máximo, por lo que esto no puede describir a los más gravemente afectados, y el grupo control fue pequeño. Documenta un patrón fisiológico, sin establecer una causa de la enfermedad.
Who this may not transfer to:The Snell cohort was all women; the companion study by Keller included men and women and found the same failure to reproduce peak oxygen uptake on the second day, so the pattern is not thought to be specific to women.
The studies · 2
Snell et al., discriminative validity of metabolic and workload measurements for identifying people with chronic fatigue syndrome · Phys Ther 2013;93(11):1484-92
Keller et al., inability of myalgic encephalomyelitis/chronic fatigue syndrome patients to reproduce VO2peak indicates functional impairment · J Transl Med 2014;12:104
A caution on exercise
Extra restraintEverything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.
El ejercicio gradual empeoró los síntomas del 54 % al 74 % de los pacientes encuestados, mientras que la dosificación del esfuerzo ayudó al 44 % al 82 %
En una encuesta primaria de 1428 pacientes y encuestas de comparación que suman 16,665 más, la terapia de ejercicio gradual fue seguida de un empeoramiento de los síntomas en el 54 % al 74 % de los encuestados. La terapia cognitivo-conductual ayudó a una pequeña parte (8 % al 35 %). La dosificación del esfuerzo fue el enfoque más favorecido, con la tasa más baja de daño reportado y el beneficio reportado más alto (44 % al 82 %). Los datos de encuesta captan lo que los pacientes reportan después de los hechos, no una comparación controlada, por lo que no pueden medir el tamaño del efecto con precisión; aun así, el tamaño y la consistencia de la señal de daño para el ejercicio gradual en encuestas independientes es lo que sopesó la guía actual.Geraghty et al., ME/CFS patients' reports of symptom changes following CBT, GET and pacing treatments: analysis of a primary survey compared with secondary surveys
Do not push through the fatigue
The instinct to exercise your way back to fitness is the one that backfires here. In ME/CFS, structured graded exercise made a large share of people worse, and current guidance no longer recommends it as a treatment. Pacing to avoid post-exertional crashes is the approach that holds up. The advice that helps ordinary deconditioning is the opposite of what helps here.
Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.
When to Get Checked
When to See Someone
Most of living with ME/CFS is steady, day-to-day energy management. A few situations call for a professional. One comes first: a doctor should make this diagnosis after ruling out other causes. These are the signs to get seen about:
- A first assessment: months of these symptoms need a doctor to rule out the treatable causes above before settling on ME/CFS
- Fatigue alongside unexplained weight loss, a fever that will not settle, drenching night sweats, or a new lump, which points toward a cause that needs looking into promptly(seek urgent care)
- A steep, lasting deterioration, or very severe illness where someone cannot take in enough food or fluid, which needs prompt medical help(seek urgent care)
- Fainting, chest pain, or a new or severe pounding or racing heart, which should be assessed(seek urgent care)
- New or worsening neurological symptoms: weakness in a limb, loss of coordination, double vision or trouble speaking, not part of ME/CFS, and needing review(seek urgent care)
- Thoughts of harming yourself or ending your life: contact your local emergency number or crisis line now, and tell someone nearby(seek urgent care)
- Low mood or anxiety: common alongside a disabling illness, and deserving care in its own right
- Any plan to start or stop a prescribed medicine, those changes belong with whoever prescribed it
ME/CFS is a serious illness, and much of what steadies it is self-directed, once a doctor has confirmed the diagnosis and ruled out other causes.
The Chinese Medicine View
The Chinese Medicine View
Chinese medicine reads a long, depleting illness like this as a vacuity pattern, the body drained of its resources. It centers on the Spleen, held responsible for making qi from food, and the Kidney. These patterns come from a system used to steady depleted people for well over a thousand years. Not everything that helps a fatigued person shows up in a trial. The tradition holds back too. A depleted person is not given strong draining, purging or stimulating methods; those deepen the exhaustion. The idea that vigorous exercise can restore a depleted person runs against the same caution that modern pacing teaches. The herb choice follows the pattern, so a formula that suits one person can be wrong for the next. Any herbs belong with a qualified practitioner.
Heavy, tired limbs, poor appetite, loose stools, bloating after eating, and a foggy head that worsens with effort. The classical direction is to strengthen the Spleen and build qi gently, so the person is not pushed past what they can hold.
A deep, bone-level exhaustion, low back and knee weakness, feeling cold, poor stamina and low drive. The tradition sees the Kidney as the root of reserve energy, and this pattern points to supporting it slowly.
The picture that often follows a viral illness: low-grade feverishness or night sweats, a dry throat, restless unrefreshing sleep, and a crash after exertion. The direction is to clear what lingers while rebuilding qi and yin, and to avoid overtreating a person who is already depleted.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 10 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 9, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.